Journal article
Sulodexide versus Control and the Risk of Thrombotic and Hemorrhagic Events: Meta-Analysis of Randomized Trials
Abstract
Thrombotic cardiovascular disease (myocardial infarction [MI], stroke, and venous thromboembolism [VTE]) remains a major cause of death and disability. Sulodexide is an oral glycosaminoglycan containing heparan sulfate and dermatan sulfate. We conducted a systematic review and meta-analysis to determine the cardiovascular efficacy, and safety of sulodexide versus control in randomized controlled trials (RCTs). We searched MEDLINE, Embase, and …
Authors
Bikdeli B; Chatterjee S; Kirtane AJ; Parikh SA; Andreozzi GM; Desai NR; Francese DP; Gibson CM; Piazza G; Goldhaber SZ
Journal
Seminars in Thrombosis and Hemostasis, Vol. 46, No. 08, pp. 908–918
Publisher
Thieme
Publication Date
November 2020
DOI
10.1055/s-0040-1716874
ISSN
0094-6176